Frank David 7/10/13 Frank David 7/10/13

Why oncology companies should care about drug adherence

Many companies think adherence isn't an issue in cancer care. They're wrong.

Frank David 6/4/13 Frank David 6/4/13

New drugs less effective than old ones? Not so fast...

Q: Are we really making worse drugs now than we used to, as suggested by a recent high-profile news article? A: No. And I'll explain why.

Frank David 5/8/13 Frank David 5/8/13

It's time to stop demonizing research interactions between physicians and Pharma, and start fighting rhetorical fire with hard data.

Frank David 4/25/13 Frank David 4/25/13

A few more thoughts on drug pricing, following up on a prior post.

Frank David 4/21/13 Frank David 4/21/13

We have tools available today to improve the drug pricing system. Let's start using them.

Frank David 4/9/13 Frank David 4/9/13

If Pharma companies want to succeed in cancer R&D, they need to get better at handling combinations. Here are some places to start.